Progress in Radiopharmacy: Developments in Nuclear Medicine, cartea 22
Editat de August P. Schubiger, Gerrit Westeraen Limba Engleză Hardback – 31 dec 1991
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1407.16 lei 43-57 zile | |
SPRINGER NETHERLANDS – 25 sep 2012 | 1407.16 lei 43-57 zile | |
Hardback (1) | 1414.29 lei 43-57 zile | |
SPRINGER NETHERLANDS – 31 dec 1991 | 1414.29 lei 43-57 zile |
Din seria Developments in Nuclear Medicine
- 5% Preț: 346.15 lei
- 5% Preț: 3201.77 lei
- 5% Preț: 1100.09 lei
- 5% Preț: 376.43 lei
- 5% Preț: 2118.14 lei
- 5% Preț: 373.68 lei
- 5% Preț: 1419.03 lei
- 5% Preț: 1413.35 lei
- 5% Preț: 653.14 lei
- 5% Preț: 369.65 lei
- 5% Preț: 717.93 lei
- 5% Preț: 710.60 lei
- 5% Preț: 367.64 lei
- 5% Preț: 711.32 lei
- 5% Preț: 2130.92 lei
- 5% Preț: 715.35 lei
- 5% Preț: 1097.36 lei
- 5% Preț: 715.55 lei
- 5% Preț: 1105.40 lei
- 5% Preț: 368.37 lei
- 5% Preț: 708.23 lei
- 5% Preț: 1094.80 lei
- 5% Preț: 363.44 lei
- 5% Preț: 1098.12 lei
- 5% Preț: 1098.27 lei
- 5% Preț: 1100.09 lei
- 5% Preț: 1096.10 lei
- 5% Preț: 722.33 lei
- 5% Preț: 363.38 lei
- 5% Preț: 361.96 lei
- 5% Preț: 376.43 lei
- 15% Preț: 588.00 lei
- 5% Preț: 380.10 lei
- 5% Preț: 375.34 lei
- 5% Preț: 369.10 lei
Preț: 1414.29 lei
Preț vechi: 1488.72 lei
-5% Nou
Puncte Express: 2121
Preț estimativ în valută:
270.63€ • 283.27$ • 225.25£
270.63€ • 283.27$ • 225.25£
Carte tipărită la comandă
Livrare economică 31 martie-14 aprilie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780792315254
ISBN-10: 0792315251
Pagini: 228
Ilustrații: XIII, 228 p.
Dimensiuni: 155 x 235 x 16 mm
Greutate: 0.53 kg
Ediția:1992
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Nuclear Medicine
Locul publicării:Dordrecht, Netherlands
ISBN-10: 0792315251
Pagini: 228
Ilustrații: XIII, 228 p.
Dimensiuni: 155 x 235 x 16 mm
Greutate: 0.53 kg
Ediția:1992
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Nuclear Medicine
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
1. Future development of radiopharmaceuticals.- One: Brain receptor ligands.- 2. Necessary conditions for a multicenter study with a new radiopharmaceutical. Example: 123 I-Iomazenil.- 3. Design and evaluation of new receptor ligands exemplified by recent developments in the pharmacology of the benzodiazepine receptor.- 4. Studies on substituted benzamides as brain dopamine receptor imaging agent.- Two: Technetium-99m and other radionuclide generators.- 5. Cell labeling in radiopharmacy: what can radiolabeled monoclonal antibodies offer?.- 6. Automated systems for the preparation of Tc-kits in hospitals.- 7. New radiopharmaceuticals based on Technetium.- 8. The development of new radionuclide generator systems for nuclear medicine applications.- Three: Positron Emission Tomography.- 9. Production and application of oxygen-15; radiopharmacy aspects.- 10. Clinical aspects of positron emission tomography.- 11. Carbon-11 radiopharmaceuticass - radiopharmacy aspects.- 12. Production and distribution of 18F-radiopharmaceuticals - 2-deoxy-2[18F]fluoro-D-Glucose — radiopharmaceutic aspects.- 13. Preclinical data necessary to assess PET examinations.- Four: Rules and regulations.- 14. EEC directives and radiopharmaceuticals: the point of view of the radiopharmaceutical industry.- 15. European regulations and guidelines for the registration of radiopharmaceuticals.- 16. General guidelines for the quality assurance and quality control of short-lived radiopharmaceuticals.- 17. Legal and regulatory aspects of PET radiopharmaceuticals in the USA.- Five: Education.- 18. The development of a co-ordinated training programme in radiopharmacy in Europe.- 19. Experiences in postgraduate education of radiochemists and radiopharmacists at Berlin- Buch.- Six: Appendix.- 20. Monoclonalchimeric antibodies to HIV-1 - Clinical perspectives.- 21. Tracer technique - the Swiss story.
Recenzii
'...results in a publication that should serve as a useful resource for radioharmacists, radiopharmaceutical scientists, and nuclear medicine clinicians working in academic and research environments.' Clinical Nuclear Medicine Sep. 1992